Adelaide-based Nova Eye Medical has enrolled the first patient in its multicentre study to assess the effectiveness, safety and quality of life outcomes of the canaloplasty procedure using its new iTrack Advance device. Read more
Australian surgeon spearheads global canaloplasty data registry
Australian ophthalmologist Dr Nathan Kerr has spearheaded the development of a global data registry to collect prospective, multicentre, longitudinal data for canaloplasty in glaucoma treatment. Read more
Glaukos announces FDA clearance for iStent infinite
Ophthalmic medical technology and pharmaceutical company Glaukos Corporation has received clearance from the US Food and Drug Administration (FDA) for its iStent infinite trabecular micro-bypass system. Read more
AbbVie and iSTAR Medical form glaucoma treatment alliance
Biopharmaceutical company AbbVie and Belgium medical technology manufacturer iSTAR Medical have announced a strategic alliance to further develop and commercialise iSTAR Medical’s MINIject, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. Read more
Australia to boast APAC region’s fastest-growing MIGS market
The MIGS devices market in Australia is set to be the fastest-growing in the Asia-Pacific (APAC) region, buoyed by the Federal Government’s 2020 decision to reimburse MIGS as a standalone procedure, according to a new report. Read more
New five-year data for MIGS device
Half a decade of data on the second generation iStent inject has shown a significant reduction in intraocular pressure (IOP) and medication burden in glaucoma patients. Read more
Nova Eye Medical officially launches next-gen iTrack Advance
ASX-listed ophthalmic technology company Nova Eye Medical expects more cataract surgeons and comprehensive ophthalmologists to uptake its glaucoma canaloplasty procedure, with the launch of its improved iTrack device in select Europe and Asia Pacific markets this week. Read more
Aussie study offers new MIGS head-to-head comparison
Australian ophthalmologists have published the first independent head-to-head comparison of two leading minimally invasive glaucoma surgery (MIGS) devices, finding no significant difference in intraocular pressure (IOP) outcomes but a potential greater reduction in medication use in one group. Read more
The future of glaucoma detection and monitoring
Glaucoma affects an estimated 300,000 Australians but half of them don’t know it. Early detection is considered vital to prevent irreversible vision loss and blindness. Read more
$300k grant to commercialise Aussie test for assessing glaucoma risk
A pioneering solution for assessing glaucoma risk in clinical settings is closer to commercialisation with the support of a $304,000 state government seed grant. Read more